NAVERIS

• 20/09/2022
• Series A
• $33,400,000

Our mission at NAVERIS is to deliver innovations in technology with the potential to transform cancer detection, drug development, and clinical trials.

Early detection of malignant cancers is critical to ensuring that tumors can be effectively treated with a favorable prognosis for patients. To this end, we are developing several related technologies with the potential to offer highly sensitive and specific cancer detection through blood analysis. Our flagship technology is a liquid biopsy blood test that analyzes tumor DNA in the circulation to detect specific subtypes of cancer. In clinical studies, this test has established its ability to detect cancers early – in many cases months before patients would be symptomatic given current clinical practice.

Complementing these efforts, we are also leveraging innovations in 3D biomimetic technology to provide more accurate ex vivo models for every stage of drug development – ranging from target ID & HTS to lead optimization & validation.

Our 3D biomimetic technology replicates the morphological, signaling and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, our technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.

---

---